NREP
NEW REPRESENTATIVE AT IB RECEIVED
04/28/2024
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Quick snapshot
MABLINK
ST13
US500000079299550Class
Filing
Registration
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Case type
Recorded events
Latest update
Classification
Trademark type
Nice classes
Filing date
Registration date
Expiration date
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Structured fields from the responsible authority and the official record.
Status date
Last transaction
Responsible office
Status code
Official register
Drawing code
Owner type
Owner location
Examiner
Law office
Current location
Holders
Representatives
John R. Rudolph Eli Lilly and Company
Nice Classes
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Chemical, biochemical, biological and biotechnological preparations for use in industry and science ; chemical substances for the manufacture of pharmaceutical products for non-medical purposes, namely, for use in manufacturing of antibody conjugates ; chemical substances for tethering molecules, in particular chemical substances for tethering molecules for cancer therapy, for research in active substances and medicines other than for medical or veterinary purposes; chemical substances for the formation of antibody conjugates for use in laboratories, other than for medical or veterinary purposes ; chemical reagents for scientific purposes other than for medical or veterinary purposes; reagents for scientific or medical research; chemical, biochemical and biological reagents for scientific or medical research use; chemicals for bioconjugation, reversible cysteine protection, surface modification, and the production of prodrugs for use in laboratories, other than for medical or veterinary purposes; antibodies and antibody conjugates for scientific purposes, other than for medical or veterinary purposes; antibodies for scientific or medical research; molecules and biomolecules, namely, reagents, antibody fragments, antibodies, all intended for fundamental research and development, medical research and scientific diagnosis; Diagnostic products for scientific or research use related to conjugated antibodies, namely, diagnostic preparations for scientific use
Class 5
Pharmaceutical preparations for the treatment of cancer ; pharmaceutical products for the prevention or treatment of human diseases, namely, the treatment of cancer; chemical, biological and biochemical products for medical and pharmaceutical use, namely, antibody-drug conjugates and any protein combined with a drug, a polynucleotide, another protein, a chemical entity, or another functional entity, and used as medical binders or fillers; pharmaceutical preparations, namely bioconjugates, intended for the diagnosis and treatment of diseases, namely, cancer ; antibody products, namely, antibody or protein bioconjugates for the medical diagnosis and treatment of cancer, namely, antibody/protein drug conjugates, antibody/protein labeled conjugates and antibody/protein imaging agent conjugates; delivery devices for antibodies, namely, drugs delivery agent in the form of antibodies drug conjugates that facilitate the delivery and action of medical preparations ; molecules and biomolecules, namely, reagents, antibody fragments, antibodies, all intended for medical diagnosis and disease treatment; pharmaceutical products, preparations and medical articles, namely, antibodies, antibody conjugates and active principles and antibody conjugates for medical purposes; chemical reagents for medical use, namely, chemical reagents to bind molecules for medical use; chemical reagents for the functionalization of biomolecules for medical use
Class 40
Preparation, transformation, processing of biopharmaceutical materials, reagents, antibodies and conjugated antibodies, namely, biomanufacturing for others, namely, manufacturing of pharmaceuticals using biological organisms in the manufacturing process; processing and transformation of biopharmaceuticals on behalf of third parties; custom manufacturing of scientific, medical, chemical, biochemical and pharmaceutical products, namely, conjugated antibodies and drug conjugate by biopharmaceutical compounders
Class 42
Scientific research; biological and chemical research; biochemical research and development; research and development in the pharmaceutical, biomedical and biotechnological fields, namely, research into antibodies, including conjugated antibodies; research and development in the fields of biological development and biomanufacturing; laboratory research, analysis, evaluation, development and clinical testing of therapeutic, preventive and diagnostic compositions and treatments; conducting scientific and medical research for third parties in the field of pharmaceuticals and cancer therapy ; consultancy in the field of pharmaceutical research, chemistry, biotechnology; Performance of chemical analyses, namely, custom synthesis of chemical substances; chemical and biological development services, namely custom design and development of chemical reagents and biochemical assays; services of a chemist and a biologist; scientific laboratory services namely chemical and biological laboratory services; scientific laboratory services, namely, laboratory services concerning the modification and production of reagents, antibodies and conjugated antibodies; scientific research and development services in the field of reagent development and production of antibodies and conjugated antibodies; conducting chemical and biological analyses; customized design and development of chemical reagents, antibodies and conjugated antibodies; development of chemical substances, namely, chemical substances to tether molecules and in particular technological platforms for the creation or improvement of antibody-drug conjugates or any protein combined with a drug, a polynucleotide, another protein, a chemical entity or another functional entity intended for industry and science
Class 44
Medical services; medical services, namely, medical modification of antibodies; medical services in the field of personalized medicine; medical advice and information services in the field of biopharmaceutical products; pharmaceutical advice; consultancy services in the field of medicine
History of USPTO decisions and trademark events.
32 publications found
NEW REPRESENTATIVE AT IB RECEIVED
04/28/2024
TEAS CHANGE OF CORRESPONDENCE RECEIVED
03/14/2024
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
03/14/2024
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
03/14/2024
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
03/14/2024
TEAS CHANGE OF OWNER ADDRESS RECEIVED
03/14/2024
FINAL DECISION TRANSACTION PROCESSED BY IB
05/09/2022
FINAL DISPOSITION NOTICE SENT TO IB
04/18/2022
FINAL DISPOSITION PROCESSED
04/18/2022
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
01/26/2022
REGISTERED-PRINCIPAL REGISTER
10/26/2021
NOTIFICATION PROCESSED BY IB
08/15/2021
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
08/10/2021
PUBLISHED FOR OPPOSITION
08/10/2021
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
07/28/2021
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
07/28/2021
NEW REPRESENTATIVE AT IB RECEIVED
07/23/2021
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
07/21/2021
APPROVED FOR PUB - PRINCIPAL REGISTER
07/05/2021
TEAS/EMAIL CORRESPONDENCE ENTERED
06/24/2021
CORRESPONDENCE RECEIVED IN LAW OFFICE
06/24/2021
TEAS RESPONSE TO OFFICE ACTION RECEIVED
06/24/2021
REFUSAL PROCESSED BY IB
01/24/2021
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
01/05/2021
REFUSAL PROCESSED BY MPU
01/05/2021
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
12/19/2020
NON-FINAL ACTION WRITTEN
12/18/2020
ASSIGNED TO EXAMINER
12/17/2020
APPLICATION FILING RECEIPT MAILED
12/15/2020
ASSIGNED TO EXAMINER
12/11/2020
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
12/11/2020
SN ASSIGNED FOR SECT 66A APPL FROM IB
12/10/2020
Continuous trademark protection
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.